

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.
30610/40037

Serial No.
10/812,849

INFORMATION DISCLOSURE STATEMENT

Applicant
Zankel *et al.*

Filing Date
March 30, 2004

Group
~~1614~~ 1649

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate
DK	A1	4,018,884	04/19/1977	Cleeland, Jr. <i>et al.</i>	436	547	
	A2	4,391,904	07/05/1983	Litman <i>et al.</i>	435	7.91	
	A3	4,394,448	07/19/1983	Szoka, Jr. <i>et al.</i>	435	458	
	A4	4,744,981	05/17/1988	Pavanasasivam	424	181.1	
	A5	4,897,255	01/30/1990	Fritzberg <i>et al.</i>	530	391.5	
	A6	4,988,496	01/29/1991	Srinivasan <i>et al.</i>	424	1.53	
	A7	5,106,951	04/21/1992	Morgan, Jr. <i>et al.</i>	530	391.9	
	A8	5,186,941	02/16/1993	Callahan <i>et al.</i>	424	450	
	A9	5,474,766	12/12/1995	Schwartz <i>et al.</i>	424	94.64	
	A10	5,962,012	10/05/1999	Lin <i>et al.</i>	424	448	
	A11	5,981,194	11/09/1999	Jeffries <i>et al.</i>	435	7.1	
	A12	6,261,595	07/17/2001	Stanley <i>et al.</i>	424	449	
	A13	6,447,775	09/10/2002	Strickland <i>et al.</i>	424	130.1	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes	No
DK	B1	WO 01/59459	08/16/2001	PCT				
DK	B2	WO 02/13843	02/21/2002	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

DK	C1	Altschul <i>et al.</i> , <i>J. Mol. Biol.</i> , 215 (3):403-410 (1990)
	C2	Ashcom <i>et al.</i> , <i>J. Cell. Biol.</i> , 110 (4):1041-1048 (1990)
	C3	Bickel <i>et al.</i> , <i>Adv. Drug Deliv. Rev.</i> , 46 (1-3):247-279 (2001)
	C4	Blair <i>et al.</i> , <i>J. Immunol. Methods</i> , 59 (2):129-143 (1983)
	C5	Blättler <i>et al.</i> , <i>Biochem.</i> , 24 :1517-1524 (1985)
	C6	Bu <i>et al.</i> , <i>J. Biol. Chem.</i> , 271 (36):22218-22224 (1996)
	C7	Bu <i>et al.</i> , <i>Trends Cell. Biol.</i> , 8 (7):272-276 (1998)
	C8	Czekay <i>et al.</i> , <i>Mol. Biol. Cell.</i> , 8 (3):517-532 (1997)
	C9	Dehouck <i>et al.</i> , <i>J. Cell. Biol.</i> , 138 (4):877-889 (1997)
	C10	Fahrlander <i>et al.</i> , <i>Bio/Technology</i> , 6 :1165-1168 (1988)
	C11	Feng <i>et al.</i> , <i>J. Mol. Evol.</i> , 25 :351-360 (1987)
	C12	Fillebeen <i>et al.</i> , <i>J. Biol. Chem.</i> , 274 (11):7011-7017 (1999)
	C13	FitzGerald <i>et al.</i> , <i>J. Cell Biol.</i> , 129 (6):1533-1541 (1995)
	C14	Genbank Accession No. AAH49517
	C15	Genbank Accession No. AAM90301
	C16	Genbank Accession No. CAA05085
	C17	Genbank Accession No. NP_506187
	C18	Genbank Accession No. NP_649950

EXAMINER /Daniel Kolker/ (08/23/2006)


DATE CONSIDERED 08/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 30610/40037	Serial No. 10/812,849
INFORMATION DISCLOSURE STATEMENT		Applicant Zankel <i>et al.</i>	
		Filing Date March 30, 2004	Group 1614 1649

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
DK	C19	Genbank Accession No. P30533
	C20	Genbank Accession No. Q99068
	C21	Genbank Accession No. X13916
	C22	Genbank Accession No. XP_132029
	C23	Genbank Accession No. XP_313261
	C24	Gutierrez <i>et al.</i> , <i>J. Neuroimmunology</i> , 47(2):169-176 (1993)
	C25	Henikoff <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 89:10915 (1989)
	C26	Herz <i>et al.</i> , <i>Atherosclerosis</i> , 118 Suppl:S37-S41 (1995)
	C27	Herz <i>et al.</i> , <i>J. Biol. Chem.</i> , 266(32):21232-21238 (1991)
	C28	Herz <i>et al.</i> , <i>J. Clin. Invest.</i> , 108(6):779-784 (2001)
	C29	Higgins <i>et al.</i> , <i>Comput. Appl. Biosci.</i> , 5(2):151-153 (1989)
	C30	Hoogerbrugge <i>et al.</i> , <i>Lancet</i> , 345(8962):1398-1402 (1995)
	C31	Jensen <i>et al.</i> , <i>FEBS Lett.</i> , 255(2):275-280 (1989)
	C32	Karlin <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 90(12):5873-5877 (1993)
	C33	Kilic <i>et al.</i> , <i>Stroke</i> , 34(5):1304-1310 (2003)
	C34	King <i>et al.</i> , <i>Biochem.</i> , 25(19):5774-5779 (1986)
	C35	Kushuhara <i>et al.</i> , <i>Drug Discov. Today</i> , 6(3):150-156 (2001)
	C36	Lin <i>et al.</i> , <i>Science</i> , 260(5111):1130-1132 (1993)
	C37	Medved <i>et al.</i> , <i>J. Biol. Chem.</i> , 274(2):717-727 (1999)
	C38	Meilinger <i>et al.</i> , <i>FEBS Lett.</i> , 360(1):70-74 (1995)
	C39	Melman <i>et al.</i> , <i>J. Biol. Chem.</i> , 276(31):29338-29346 (2001)
	C40	Needleman <i>et al.</i> , <i>J. Mol. Biol.</i> , 48(3):443-453 (1970)
	C41	Nielsen <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 94(14):7521-7525 (1997)
	C42	Orlando <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 91(8):3161-3165 (1994)
	C43	Pardridge, <i>J. Neurovirol.</i> , 5(6):556-569 (1999)
	C44	Pearson <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 85(8):2444-2448 (1988)
	C45	Rall <i>et al.</i> , <i>J. Biol. Chem.</i> , 273(37):24152-24157 (1998)
	C46	Savonen <i>et al.</i> , <i>J. Biol. Chem.</i> , 274(36):25877-25882 (1999)
	C47	Smith <i>et al.</i> , <i>Adv. Appl. Math.</i> , 2:482-489 (1981)
	C48	Srinivasachar <i>et al.</i> , <i>Biochem.</i> , 28(6):2501-2509 (1989)
	C49	SwissProt Primary Accession No. Q07954
	C50	Takahashi <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 89(19):9252-9256 (1992)
	C51	Thompson <i>et al.</i> , <i>Nucleic Acids Res.</i> , 22(22):4673-4680 (1994)
	C52	Tsuji <i>et al.</i> , <i>Adv. Drug Deliv. Rev.</i> , 36(2-3):277-290 (1999)
	C53	Warshawsky <i>et al.</i> , <i>J. Biol. Chem.</i> , 269(5):3325-3330 (1994)
	C54	Wilchek <i>et al.</i> , <i>Anal. Biochem.</i> , 171:1-32 (1988)
	C55	Williams <i>et al.</i> , <i>J. Biol. Chem.</i> , 267(13):9035-9040 (1992)
	C56	Willnow <i>et al.</i> , <i>J. Biol. Chem.</i> , 267(36):26172-26180 (1992)
↓	C57	Wisselaar <i>et al.</i> , <i>J. Biol. Chem.</i> , 268(3):2223-2231 (1993)
	C58	Yenofsky <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 87(9):3435-3439 (1990)

EXAMINER /Daniel Kolker/ (08/23/2006)	DATE CONSIDERED 08/23/2006
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



PTO/SB/08a/b (08-03)
 Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/812,849
				Filing Date	March 30, 2004
				First Named Inventor	Todd Zankel
				Art Unit	1649
				Examiner Name	Daniel E. Kolker
Sheet	1	of	1	Attorney Docket Number	31075/40037

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind-of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DK	C59	Canals et al., J. Neuroscience, 24(35):7727-7739 (2004)	
↓	C60	Ferrer et al., Brain Research, 866, 257-261 (2000)	
↓	C61	Kells et al., Molecular Therapy, 9 (5) 682-688 (2004)	
↓	C62	Spires, et al., J. Neuroscience, 24(9) 2270-2276 (2004)	
↓	C63	Zuccato et al., Science, 293, 493-498 (2001)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Daniel Kolker/ (08/23/2006)	Date Considered	08/23/2006
-----------------------	------------------------------	--------------------	------------